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Abstract  The  objective  of  this  study  was  to  evaluate  how  Brazilian  anesthesiologists  are  using
neuromuscular  blockers,  focusing  on  how  they  establish  the  diagnosis  of  postoperative  residual
curarization  and  the  incidence  of  complications  associated  with  the  use  of  neuromuscular  block-
ers. A  questionnaire  was  sent  to  anesthesiologists  inviting  them  to  participate  in  the  study.  The
online data  collection  remained  open  from  March  2012  to  June  2013.  During  the  study  period,
1296 responses  were  collected.  Rocuronium,  atracurium,  and  cisatracurium  were  the  main  neu-
romuscular blockers  used  in  cases  of  elective  surgery.  Succinylcholine  and  rocuronium  were  the
main neuromuscular  blockers  used  in  cases  of  emergency  surgery.  Less  than  15%  of  anesthesiolo-
gists reported  the  frequent  use  of  neuromuscular  function  monitors.  Only  18%  of  those  involved
in the  study  reported  that  all  workplaces  have  such  a  monitor.  Most  respondents  reported  using
only the  clinical  criteria  to  assess  whether  the  patient  is  recovered  from  the  muscle  relaxant.
Most respondents  also  reported  always  using  some  form  of  neuromuscular  blockade  reversal.
The major  complications  attributed  to  neuromuscular  blockers  were  residual  curarization  and
prolonged blockade.  Eighteen  anesthesiologists  reported  death  attributed  to  neuromuscular
blockers.  Residual  or  prolonged  blockade  is  possibly  recorded  as  a  result  of  the  high  rate  of
using clinical  criteria  to  diagnose  whether  the  patient  has  recovered  or  not  from  motor  block
and, as  a  corollary,  the  poor  use  of  neuromuscular  transmission  monitors  in  daily  practice.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
PALAVRAS-CHAVE Uso  de  bloqueadores  neuromusculares  no  Brasil pesquisa  foi  avaliar  como  os  anestesiologistas  brasileiros  estão
uromusculares  (BNM),  com  foco  na  forma  de  estabelecer  o  diag-
idual  pós-operatória  e  a  incidência  de  complicac¸ões  atribuídas  ao
rio  foi  enviado  a  anestesiologistas  convidando-os  a  participar  daBloqueadores
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nóstico da  curarizac¸ão  res
uso de  BNM.  Um  questionáneuromuscular pesquisa  (tabela  1).  A  coleta  online  de  dados  permaneceu  aberta  de  marc¸o  de  2012  a  junho
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de  2013.  Durante  o  período  de  estudo  foram  coletadas  1.296  respostas.  Rocurônio,  atracúrio
e cisatracúrio  foram  os  principais  bloqueadores  neuromusculares  usados  em  casos  de  cirurgia
eletiva. Succinilcolina  e  rocurônio  foram  os  principais  BNM  usados  em  casos  de  cirurgia  de
emergência.  Menos  de  15%  dos  anestesiologistas  referiram  que  usam  frequentemente  monitores
da func¸ão  neuromuscular.  Apenas  18%  dos  envolvidos  no  estudo  referiram  que  todos  os  locais
de trabalho  têm  tal  monitor.  A  maioria  dos  entrevistados  aﬁrmou  que  usa  somente  o  critério
clínico para  avaliar  se  o  paciente  está  recuperado  do  relaxante.  A  maioria  dos  entrevistados
também relatou  que  sempre  usa  algum  tipo  de  reversão  de  bloqueio  neuromuscular.  As  principais
complicac¸ões atribuídas  aos  BNM  foram  curarizac¸ão  residual  e  bloqueio  prolongado.  Houve
relato por  18  anestesiologistas  de  óbito  atribuído  a  BNM.  O  bloqueio  residual  ou  prolongado
se registra,  possivelmente,  como  consequência  do  alto  índice  do  uso  de  critérios  clínicos  para
diagnosticar  se  o  paciente  está  recuperado  ou  não  do  bloqueio  motor  e,  como  um  corolário,  o
baixo uso  de  monitores  da  transmissão  neuromuscular  na  prática  diária.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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Most  anesthesiologists  indicated  that  succinylcholine  and
rocuronium  were  the  main  NMB  used  in  cases  of  emergency
surgery.  Data  are  shown  in  Fig.  2.
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ostoperative  residual  curarization  (PORC)  is  a  complication
f  considerable  impact  and  proven  side  effects,  sometimes
otentially  life-threatening.1--6
The  diagnosis  of  deep  relaxation  degrees  at  the  end  of
nesthesia  can  be  done  with  the  use  of  bedside  tests;  how-
ver,  curare  residual  blocks  are  only  detected  with  the  use
f  neuromuscular  transmission  (NMT)  objective  monitoring
y  train-of-four  (TOF)  and  accelerometry.7--11 Although  there
s  a  consensus  in  the  literature  on  how  to  diagnose,  as  well
s  the  consequences  of  this  complication,  the  frequency  of
sing  NMT  monitors  remains  very  low,  even  in  developed
ountries.12--14
The  objective  of  this  study  was  to  evaluate  how  Brazilian
nesthesiologists  are  using  neuromuscular  blockers  (NMB),
ocusing  on  how  to  establish  the  diagnosis  of  PORC  and  the
ncidence  of  complications  associated  with  the  use  of  NMB,
nd  compare  the  results  with  those  obtained  in  a  similar
urvey  10  years  ago  in  Brazil15 (Table  1).
ethod
fter  approval  by  the  Human  Research  Ethics  Committee
nder  the  protocol  #  2205/2011,  an  e-mail  was  sent  to
nesthesiologists  registered  in  the  database  of  the  Brazilian
ociety  of  Anesthesiology  and  Anestech,  inviting  members
o  participate  in  the  survey  ‘‘Use  of  neuromuscular  block-
rs  in  Brazil’’.  In  the  email  message  body,  participants  were
nformed  that  participation  was  not  mandatory,  the  collec-
ion  of  responses  would  be  anonymous  and  data  would  be
onﬁdential  and  untraceable.  The  questionnaire  consisted
f  10  questions,  2  about  demographics  and  8  about  the
hoice  of  using  NMB,  neuromuscular  function  monitoring,
lockade  reversal,  and  complications  associated  with  the
se  of  these  drugs.
The  participants  accessed  a  link  to  a  website  for  online
ata  collection  (Survey  Monkey,  USA).  Data  collection
emained  open  from  March  2012  to  June  2013.  To  increase
he  response  rate,  three  invitations  were  sent  to  the  partic-
pants.  Data  are  presented  as  frequency  (percentage).
F
cesults
he  invitation  to  participate  in  the  survey  was  sent  to  9910
nesthesiologists.  During  the  study  period,  1296  responses
ere  collected.
Regarding  the  years  in  practice  of  anesthesiology,  there
as  a  predominance  of  anesthesiologists  with  over  11  years
f  practice  (53.8%);  30.7%  and  15.5%  of  responders  with  up
o  5  years  of  specialty  and  between  6  and  10  years,  respec-
ively.
Most  participants  were  from  the  Southeast  region
52.4%),  followed  by  participants  from  the  South  (20.6%),
ortheast  (15.6%),  Midwest  (8.4%),  and  North  (3%)  regions.
Most  anesthesiologists  who  responded  to  the  ques-
ionnaire  reported  that  rocuronium,  atracurium,  and
isatracurium  were  the  main  NMB  used  in  cases  of  elective
urgery.  These  data  are  shown  in  Fig.  1.igure  1  Most  commonly  used  NMB  for  tracheal  intubation  in
ases of  elective  surgery.  Total  of  1296  responses.
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Table  1  Questionnaire  sent  to  survey  participants.
1.  How  many  years  have  you  been  in  practice  of
anesthesiology?
Up to  5  years
Between  6  and  10  years
Over  11  years
2. What  is  the  region  where  you  exercise  your  occupation?
North
Northeast
Midwest
Southeast
South
3. Check  the  two  (2)  neuromuscular  blockers  you  use  most
for tracheal  intubation  in  cases  of  elective  surgery.
Atracurium
Cisatracurium
Rocuronium
Vecuronium
Pancuronium
Succinylcholine
Other
4. Check  the  two  (2)  neuromuscular  blockers  you  use  most
for tracheal  intubation  in  cases  of  emergency  surgery.
Cisatracurium
Rocuronium
Vecuronium
Pancuronium
Succinylcholine
Others
5. Regarding  the  use  of  neuromuscular  transmission
monitor:
Never
Rarely
Sometimes
Often
6. Hospital(s)  in  which  you  work:
All  have  the  TOF  neuromuscular  transmission  monitor
Some have  the  TOF  neuromuscular  transmission  monitor
None  has  the  TOF  neuromuscular  transmission  monitor
7. As  a  criterion  ‘‘the  patient  has  recovered  from  the
muscle  relaxant’’,  you  use:
Only  the  clinical  criteria  only
Only the  TOF  neuromuscular  transmission  monitor
The  clinical  criteria  and  the  TOF  neuromuscular
transmission  monitor
8. Do  you  use  any  type  of  neuromuscular  blockade  reversal
(neostigmine  or  sugammadex)?
Always
It depends  on  the  outcome  of  the  TOF  monitor
I do  not  use
9.  Have  you  ever  had  any  complication  that  you  assigned  to
the muscle  relaxant?
Prolonged  blockade
Residual  curarization
Severe  bronchospasm
Allergic  reaction
Table  1  (Continuación  )
Prolonged  apnea  after  succinylcholine
Malignant  hyperthermia
Serious  cardiac  dysrhythmias
Recurarization
10.  If  you  checked  any  condition  in  question  9,  in  the  case
considered  most  serious,  the  patient:
Without  sequelae
With  sequelae  that  I  considered  mild/moderate
With  sequelae
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Less  than  15%  of  anesthesiologists  who  participated  in  the
tudy  said  they  often  use  neuromuscular  function  monitor
Fig.  3).  Only  18%  of  respondents  reported  that  all  work-
laces  have  such  a  monitor  (Fig.  4).
Regarding  the  reversal  of  neuromuscular  blockade  at
he  end  of  anesthesia,  the  majority  of  respondents  said
hat  they  use  only  the  clinical  criteria  to  assess  whether
he  patient  has  recovered  from  the  muscle  relaxant.
ost  respondents  also  reported  always  using  some  sort  of
euromuscular  blockade  reversal  agent  (neostigmine  or  sug-
mmadex)  at  the  end  of  anesthesia.  Data  are  shown  in
igs.  5  and  6.
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igure  2  Most  commonly  used  NMB  for  tracheal  intubation  in
ases of  emergency  surgery.  Total  of  1294  responses.
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Figure  4  Availability  of  TOF  neuromuscular  transmission  mon-
itor at  the  workplaces  of  1292  anesthesiologists.
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Figure  5  Criterion  used  to  evaluate  patient  recovery  after
neuromuscular  blockade  by  1291  anesthesiologists.
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Figure  6  Use  of  neuromuscular  blockade  reversal  (sugam-
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Figure  7  Complications  attributed  to  the  use  of  NMB  by  1160
anesthesiologists.
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Succinylcholine  remains  the  drug  of  choice  by  respondentsadex  or  neostigmine)  at  the  end  of  anesthesia.  Total  of  1296
esponses.
The  complications  associated  with  the  use  of  NMB  are
escribed  in  Fig.  7.  Residual  curarization  and  prolonged
lockade  were  the  main  complications.  Most  respondents
ndicated  that  patients  evolved  without  sequelae  after
omplications,  but  18  anesthesiologists  reported  death  asso-
iated  with  NMB  (Fig.  8).
iscussion
n  this  study,  13%  of  questionnaires  were  completed  (1296
f  9910  questionnaires  sent).  We  found  a  percentage  of
esponses  similar  to  Naguib  et  al.,16 whose  percentage  was
0%  (1792  of  17,870)  in  the  United  States  and  15%  (844
f  4807)  in  Europe.  Phillips  et  al.,17 in  Australia  and  New
ealand,  reported  a  slightly  higher  number  in  percentage
erms  (21%).  However,  the  total  number  of  respondents  was
imited  to  678.
f
t
sigure  8  Evolution  of  patients  with  complications  attributed
o the  use  of  NMB.  Total  of  1156  responses.
ain  NMB  used
he  main  NMB  used  in  Brazil  for  elective  surgical  pro-
edures  are  rocuronium,  atracurium,  and  cisatracurium.
esults  reported  in  a  previous  study  showed  that  the  NMB
ommonly  used  10  years  ago  were  atracurium,  pancuro-
ium,  and  succinylcholine.15 In  other  parts  of  the  world
ts  use  is  slightly  different.  Naguib  et  al.16 reported  that,
n  Europe,  the  three  most  commonly  used  neuromuscular
locking  agents  are  rocuronium  (75%),  atracurium  (49%),  and
uccinylcholine  (47%)  and,  in  the  United  States,  rocuronium
89%),  vecuronium  (63%),  and  atracurium  (47%).  Speciﬁ-
ally  in  France,  the  most  used  NMB  are  atracurium  and
isatracurium.18 We  could  say  that,  in  the  USA,  there  is
 greater  tendency  toward  using  steroidal  NMB,  whereas
n  France  are  the  benzylisoquinoline  neuromuscular  block-
ng  agents.  In  Brazil  there  is  a  more  even  distribution  of
oth  steroidal  NMB  and  benzylisoquinoline  agents.  We  could
xplain  this  difference  between  countries  by  market  supply
easons  and  the  incidence  of  adverse  effects,  particularly
naphylactic  reactions,  which  seem  to  be  different  in  dif-
erent  parts  of  the  world.19--22
mergency  tracheal  intubationor  emergency  tracheal  intubation,  a  result  similar  to
hat  found  in  a  previous  study,15 with  rocuronium  as  a
econd  option  currently.  The  same  result  was  found  by
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Eldawlatly  et  al.23 in  the  Middle  East  and  by  Naguib  et  al.16
in  Europe  and  the  USA.  This  can  be  explained  by  the  rapid
onset  of  action  and  the  clinical  ultrashort  duration  of
succinylcholine.  Rocuronium  has  emerged  as  an  option  due
to  its  similar  proﬁle  of  onset  of  action  and  especially  the
possibility  of  rapid  reversal  with  sugammadex.  Sugammadex
at  a  dose  of  16  mg  kg−1 is  able  to  completely  reverse  the
deep  neuromuscular  blockade  induced  by  rocuroniumin
in  less  time  than  the  spontaneous  recovery  of  1  mg  kg−1
dose  of  succinylcholine.24 With  such  ﬂexibility  of  use,  it
can  be  supposed  that  the  introduction  of  sugammadex  in
the  European  market  is  the  cause  of  increased  rocuronium
consumption  in  France.18
Clinical  criteria  to  diagnose  the  end  of  the
blockade
Most  Brazilian  anesthesiologists  remain  using  clinical  crite-
ria  to  diagnose  the  end  of  muscle  relaxation,15 such  as  the
registered  in  Australia  and  New  Zealand.17 This  is  a  ques-
tionable  conduct,  as  several  authors  have  shown  that  the
clinical  tests  alone  or  in  combination  have  low  sensitivity
and  speciﬁcity  in  the  diagnosis  of  residual  neuromuscular
blockade.
Residual  neuromuscular  blockade  may  be  present  despite
the  use  of  subjective  monitors  of  neuromuscular  function,
clinical  trials,  and  reversing  agents.25,26 Only  the  objective
monitoring  of  neuromuscular  function  is  able  to  diagnose  the
degree  of  residual  neuromuscular  blockade,  and  currently  it
is  considered  that  the  T4/T1  ratio  by  TOF  must  be  equal  to
or  preferably  higher  than  0.9  to  be  considered  absence  of
residual  neuromuscular  blockade.  Di  Marco  et  al.,  in  a  study
of  the  residual  curarization  knowledge  in  Italy,  reported
that  only  24%  of  anesthesiologists  responded  that  the  safe
T4/T1  ratio  for  tracheal  extubation  was  0.9.27 This  result
is  similar  to  others  reported  in  Australia  and  New  Zealand,
where  anesthesiologists  considered  the  T4/T1  ratio  ≥0.9
as  an  acceptable  criterion  for  safe  tracheal  extubation.17
The  present  survey  results  show  that  in  Brazil  only  4.6%  use
only  monitor  for  the  diagnosis  of  muscle  relaxation  recov-
ery.  Probably  it  is  not  only  due  to  the  outdated  scientiﬁc
knowledge  by  the  anesthesiologist,  but  also  the  lack  of  neu-
romuscular  function  monitors.
Monitor  use  and  availability  of  monitors
This  survey  showed  that  only  14%  of  Brazilian  anesthesiol-
ogists  routinely  use  objective  monitoring  of  neuromuscular
function,  a  result  quite  close  to  that  found  in  Australia  and
New  Zealand  (17%)17 and  much  lower  than  the  percentage
in  France,  which  is  52%  when  using  single  dose  of  NMB  and
74%  when  using  maintenance  doses.28
In  this  survey,  only  18%  of  the  Brazilian  respondents’
workplaces  have  neuromuscular  function  monitor.  These
results  are  similar  to  those  found  in  the  USA  (22%)  and  dif-
fer  widely  from  those  found  in  Europe  (70%),16 although  in
the  Brazilian  study  there  is  no  separation  of  qualitative  and
quantitative  monitors.  In  Australia  and  New  Zealand,  quan-
titative  neuromuscular  function  monitors  are  available  in
t
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8%  of  hospitals  where  respondents  practice  anesthesia,  a
umber  greater  than  that  found  in  Brazil.17
eversing  NMB
egarding  the  reversal  of  neuromuscular  blockade,  we  found
hat  almost  half  the  anesthesiologists  always  uses  reversal
gents,  either  sugammadex  or  neostigmine.  This  fact  may  be
 result  of  the  unavailability  of  NMT  monitors  in  most  Brazil-
an  hospitals.  However,  this  approach  may  be  questioned  as
he  use  of  neostigmine  after  neuromuscular  blockade  com-
lete  recovery  may  result  in  muscle  weakness.  We  found
hat  only  14%  stated  that  the  use  of  reversal  agent  is  condi-
ioned  to  the  results  of  TOF.  This  percentage  is  lower  than
hat  found  among  anesthesiologists  in  the  Middle  East23 and
ould  be  explained  by  the  lack  of  NMT  monitors  in  Brazil.
omplications  of  using  NMB  and  reversal
he  complications  most  often  cited  in  this  survey  are  the
esidual  neuromuscular  blockade  followed  by  prolonged
euromuscular  blockade.  Esteves  et  al.29 found  an  incidence
f  residual  neuromuscular  blockade  of  26%  (TOF  <  0.9).  This
emonstrates  that,  despite  the  scientiﬁc  knowledge  of  the
roblem  and  the  use  of  sugammadex,  a  high  incidence  of
his  complication  still  remains.30
In  Brazil,  the  use  of  clinical  criteria  to  monitor  the  end
f  neuromuscular  blockade  and  the  lack  of  objective  moni-
oring  of  NMT  may  be  one  of  the  causes  of  this  problem.  In
ustralia  and  New  Zealand,  71%  of  respondents  in  a  survey
nderestimate  the  incidence  of  residual  curarization.17
Residual  neuromuscular  blockade  may  result  in  severe
linical  complications.31,32
The  data  of  this  survey  show  that  26%  reported  aller-
ic  reactions  as  a  complication  of  using  NMB.  Among  the
gents  used  in  anesthesia,  NMB  are  the  ones  that  cause
ost  anaphylaxis,  with  a  percentage  of  58%.19,33 The  inci-
ence  of  allergic  reactions  during  anesthesia  retrieved  from
he  French  national  database  is  greater  than  the  previous
stimate.33 Chong  et  al.  found  that  NMB  were  the  causative
gents  of  anaphylaxis  during  general  anesthesia  in  a  series
f  23  patients  with  anaphylactic  shock.34
Prolonged  apnea  reported  by  9%  and  serious  cardiac
rrhythmias  by  2%  of  respondents  to  this  survey  are  listed  in
he  results  of  the  study  by  Karanovic´  et  al.35 who  reported
he  most  common  adverse  events  reported  for  succinyl-
holine:  myalgia  (47%),  prolonged  blockade  (36%),  allergic
eaction  (13%),  and  asystole  (12%).  A  systematic  review  by
brishami  et  al.36 demonstrated  that  there  is  no  evidence
f  differences  in  the  prevalence  of  adverse  events  between
ugammadex,  placebo,  or  neostigmine.
In  this  survey,  malignant  hyperthermia  has  also  been
eported  as  a  complication  of  using  NMB  by  1.8%  of  respon-
ents.  This  demonstrates  the  concern  about  this  extremely
erious  complication,  with  the  outcome  almost  always  unfa-
orable.  This  information  needs  further  clariﬁcation,  given
hat  the  role  of  non-depolarizing  NMB  does  not  seem  to  be
nvolved  in  the  pathogenesis  of  malignant  hyperthermia  and
he  role  of  succinylcholine  as  a  trigger  of  malignant  hyper-
hermia  remains  controversial.37
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224  
volution  of  patients  with  complications  after  the
se of  NMB
n  this  survey,  the  consequences  arising  from  complications
f  using  NMB  were  considered  severe  in  0.5%  of  cases  and
ith  death  1.6%.  This  result  demonstrates  that  the  use  of
MB  may  be  related  to  unfavorable  outcomes,  as  demon-
trated  by  Naguib  et  al.,16 Eikermann  et  al.,5 and  Murphy
t  al.7,38,39 The  justiﬁcation  could  be  found  in  the  very
esults  of  this  survey:  the  use  of  clinical  criteria  for  residual
euromuscular  blockade  diagnosis,  low  use  and  low  avail-
bility  of  quantitative  NMT  monitors,  inappropriate  use  of
eversal  agents,  and  possibly  the  proper  inadequate  diagno-
is  and  treatment  of  complications  could  explain  the  serious
dverse  outcomes.
tudy  limitations
he  electronic  means  used  did  not  reach  all  recipients,  due
o  spam  type  mechanism  or  some  outdated  e-mails  in  the
atabase  used,  which  may  have  hampered  the  participation
f  a  larger  number  of  anesthesiologists.
We  conclude  by  this  survey  on  the  use  of  NMB  in  Brazil
hat  the  following  aspects  stood  out:  succinylcholine  is  still
he  most  frequently  used  NMB  for  emergency  situations,  the
ates  of  PORC  and  prolonged  muscular  block  are  high,  as
ell  as  the  record  of  sequelae  considered  serious  or  even
eath  as  complications  of  using  these  drugs.  The  residual  or
rolonged  blockade  is  possibly  seen  as  a result  of  the  high
ate  of  using  clinical  criteria  to  diagnose  whether  the  patient
as  recovered  or  not  from  motor  block  and,  as  a  corollary,
he  low  use  of  NMT  monitors  in  daily  practice.
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